⏳
Showing Q4 2024 data
XR Securities LLC's Q4 2025 filing not yet available. Expected by Feb 14, 2026.
XR Securities LLC
•CIK: 1531971•Filing: Q4 2024
**XR Securities LLC** maintains a focused, multi-sector portfolio with $5M in assets under management. The fund's current allocation is spread across nine distinct positions, notably overweighting Eli Lilly ($2.2M) and Spot Therapeutics ($0.7M). Further significant exposure includes Tesla ($0.6M), while the remaining capital is diversified across UNP, AXP, GE, BABA, NVDA, and NDQ. This concentrated structure suggests a tactical approach targeting high-conviction opportunities across healthcare, technology, and industrials.
Total AUM
$0
+ $5.4M in options
QoQ Performance
-100.0%
Positions
0
+ 9 options
Top 10 Concentration
100.0%
Latest Filing
Q4 2024
Top Holdings Allocation
LLY
SPOT
TSLA
UNP
AXP
GE
LLY41.8%
SPOT12.5%
TSLA12.1%
UNP7.2%
AXP6.7%
GE6.5%
BABA4.8%
NVDA4.5%
📈 Biggest Buys
+917.5%
41.8% of portfolio
📉 Biggest Sells
Sector Breakdown
Healthcare41.8%
Industrial13.8%
Communication12.5%
Consumer12.1%
Other8.6%
Financial6.7%
Technology4.5%
🚪 Exited Positionssold since Q3 2024
+89 more exited positions
Changes from Q3 2024
↑1 increased
↓8 decreased
Historical Filings
Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023